standard lymphodepletion
Sponsor Kyverna Therapeutics, INC. · listed as KYTX
READOUT
Phase 2/3
Confidence: medium
Source: clinicaltrials
standard lymphodepletion is a clinical-stage drug asset sponsored by Kyverna Therapeutics, INC., listed as KYTX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Sep 2027 (month precision, medium confidence), tied to trial NCT06193889. The asset is in Phase 2/3 and currently recruiting, studied in Myasthenia Gravis.
Next catalyst
Event typeREADOUT
Expected date2027-09-30
As disclosedSep 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06193889
PhasePHASE2;PHASE3
StatusRECRUITING
Lead sponsorKyverna Therapeutics
Listed asKYTX
Condition(s)Myasthenia Gravis; Generalized Myasthenia Gravis
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More KYTX catalysts